Assessing User Fees Under the Biosimilar User Fee Amendments of 2022: Guidance for Industry - FDA Guidance Document

Assessing User Fees Under the Biosimilar User Fee Amendments of 2022: Guidance for Industry - FDA Guidance Document | Global Key Solutions